Neurelis is a neuroscience-based specialty pharmaceutical company that focuses on addressing unmet medical needs through innovative approaches. With a strong emphasis on the central nervous system (CNS), including epilepsy and psychiatry, Neurelis aims to develop and commercialize highly differentiated therapies. Their goal is to empower individuals with neurological conditions, as well as their care partners and healthcare providers, by providing life-changing treatments.

The company's history showcases their commitment to advancing medical solutions. They have obtained orphan drug designation and fast track designation from the FDA for their lead investigational product candidate. In 2020, Neurelis received FDA approval and Orphan Drug Exclusivity for their first product.

Notably, within a year of the product's launch, over 50,000 cartons were prescribed. Neurelis' innovative platform technology, including Intravail® absorption enhancement technology and ProTek® Hydrogel™, allows them to form strategic partnerships to address unmet needs in various therapeutic areas. With a tenacious spirit and a focus on innovation, Neurelis continues to redefine the norm in therapeutics to improve the lives of those they serve